HYDERABAD, India, March 16, 2026 /PRNewswire/ -- According to Mordor Intelligence, the global prefilled syringes market is experiencing strong expansion as healthcare systems increasingly prioritize safe, convenient, and accurate drug delivery methods. The prefilled syringes market size is projected to grow from USD 9.74 billion in 2025 to USD 10.77 billion in 2026 and is expected to reach USD 18.12 billion by 2031, registering a CAGR of 10.96% during the 2026–2031 forecast period, supported by the rising adoption of biologic therapies, increasing prevalence of chronic diseases, and growing demand for self-administration devices across homecare settings.
Industry growth is strongly linked to the increasing global burden of chronic diseases such as diabetes, autoimmune disorders, and cardiovascular conditions. As treatment protocols increasingly rely on injectable therapies, healthcare providers are adopting prefilled syringes to improve dosing accuracy and patient adherence. Additionally, the expansion of vaccination programs and large-scale immunization initiatives continues to drive demand for reliable and easy-to-use injection systems. Advancements in syringe materials and manufacturing technologies are also contributing to market growth. The introduction of safety mechanisms, needle shielding systems, and polymer-based syringe designs is improving usability and reducing the risk of needlestick injuries. These innovations are encouraging broader adoption across hospitals, specialty clinics, and homecare environments.
Prefilled Syringes Market Share by Region
North America holds a significant share of the prefilled syringes market due to strong pharmaceutical manufacturing capabilities, widespread adoption of injectable biologics, and well-established healthcare infrastructure.
Europe represents another important regional market, supported by expanding vaccination programs, increasing adoption of advanced drug delivery systems, and growing investments in pharmaceutical innovation.
Asia-Pacific is emerging as a rapidly growing region due to rising healthcare expenditure, expanding pharmaceutical production capacity, and increasing demand for injectable therapies across large patient populations.
Other regions including the Middle East, Africa, and South America are also witnessing gradual adoption of prefilled syringe technologies as healthcare systems strengthen drug delivery infrastructure and improve access to modern treatments.
Prefilled Syringes Market Trends & Forecast
Rising Demand for Biologic Drug Delivery
The increasing use of biologic therapies for chronic disease management is accelerating the adoption of prefilled syringe drug delivery systems.
Growth of Self-Administration and Homecare Treatments
Prefilled syringes are gaining popularity due to their convenience, enabling patients to safely administer medications outside hospital settings.
Advancements in Safety and Needle Protection Technologies
Innovations in safety mechanisms and syringe design are improving patient safety while reducing the risk of accidental needlestick injuries.
Soumya Goud, Senior Research Manager, Mordor Intelligence, says, "The prefilled syringes market is advancing as healthcare systems prioritize safer delivery and dosing. Mordor Intelligence anchors its analysis in validated datasets and disciplined research review, providing executives a dependable reference against loosely documented market estimates."
Prefilled Syringes Market Segmentation Overview
By Material
By Application
By End User
By Geography
For a full breakdown of market dynamics, segmentation insights, regional analysis, and competitive landscape, access the details of the Mordor Intelligence report: https://www.mordorintelligence.com/industry-reports/prefilled-syringes-market?utm_source=prnewswire
Prefilled Syringes Market Competitive Outlook
The prefilled syringes market includes global pharmaceutical packaging manufacturers and medical device companies focusing on product innovation, strategic partnerships, and manufacturing expansion. Companies are investing in advanced materials, safety features, and compatibility with biologic drugs to strengthen their product portfolios and address the growing demand for safe and efficient injectable drug delivery systems.
Prefilled Syringes Companies include:
Industry Related Reports by Mordor Intelligence
Laboratory Supplies Market - The laboratory supplies market is estimated at USD 52.59 billion in 2026 and is projected to reach USD 75.93 billion by 2031, registering a CAGR of 7.62% during the forecast period. Growth is driven by increasing research activities in life sciences, rising demand for diagnostic testing, and expanding laboratory infrastructure across healthcare and academic institutions.
Subcutaneous Drug Delivery Devices Market - The subcutaneous drug delivery devices market is estimated at USD 36.74 billion in 2026 and is expected to reach USD 54.5 billion by 2031, growing at a CAGR of 8.20%. Market expansion is supported by increasing demand for self-administration devices, rising prevalence of chronic diseases, and growing adoption of biologics requiring subcutaneous delivery.
Dental Impression Materials Market - The dental impression materials market is estimated at USD 1.05 billion in 2026 and is projected to reach USD 1.59 billion by 2031, advancing at a CAGR of 8.63% during the forecast period. Growth is driven by increasing dental procedures, rising demand for restorative and prosthetic treatments, and expanding adoption of advanced dental materials in clinical practice.
About Mordor Intelligence:
Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.
With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.
For any inquiries, please contact:
media@mordorintelligence.com
https://www.mordorintelligence.com/contact-us
Logo: https://mma.prnewswire.com/media/2746908/Mordor_Intelligence_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/prefilled-syringes-market-to-surpass-usd-18-bn-by-2031-as-biologics-and-self-injection-devices-drive-adoption-says-mordor-intelligence-302714377.html
Bachem hat für das Geschäftsjahr 2025 robuste Zahlen vorgelegt und die durchschnittlichen Analystenschätzungen beim Umsatz wie beim Ergebnis übertroffen. Der Pharmazulieferer setzte 695,1 Millionen Franken um, ein Plus von 14,8 Prozent gegenüber dem Vorjahr; in Lokalwährungen lag das Wachstum sogar bei 19,2 Prozent. Im ersten Halbjahr war das Unternehmen in Lokalwährungen noch um 34 Prozent gewachsen. Unter dem Strich erzielte Bachem einen Reingewinn von 148,8 Millionen Franken und damit knapp 24 Prozent mehr als 2024. Damit lag das Unternehmen rund 30 Millionen Franken über der Konsensschätzung.
Auch auf operativer Ebene legte Bachem zu. Der EBITDA stieg um 21,8 Prozent auf 214,7 Millionen Franken, die Marge verbesserte sich um 1,8 Prozentpunkte auf 30,9 Prozent. Darin enthalten ist allerdings ein positiver Sondereffekt von 16,1 Millionen Franken aus der Standortentwicklung im Sisslerfeld sowie dem Verkauf eines Gebäudes in den USA. Bereinigt lag die EBITDA-Marge bei 28,6 Prozent und damit ungefähr auf Höhe der Markterwartungen. Aktionäre sollen an der Entwicklung teilhaben: Die Divende soll von 0,85 auf 0,90 Franken je Aktie erhöht werden.
Für Gesprächsstoff sorgt der Ausblick. Unter der neuen CEO Anne-Kathrin Stoller rückt Bachem von der bisher kommunizierten Marke eines Umsatzes von mindestens 1 Milliarde Franken ab, die 2026 erreicht werden sollte. Im aktuellen Communiqué wird dieses Mittelfristziel nicht mehr explizit erwähnt. Stattdessen stellt das Unternehmen für das laufende Jahr ein Umsatzwachstum von 35 bis 45 Prozent in Aussicht, was einer Spanne von 938 Millionen bis 1,008 Milliarden Franken entspricht. Schafft Bachem den oberen Rand, wäre die bisherige Zielmarke zwar erreicht – die weniger pointierte Formulierung dürfte aber einige Investoren veranlassen, ihre Erwartungen zu justieren.
Operativ richtet Bachem die Organisation auf weiteres Wachstum aus. 2025 investierte der Konzern 332,6 Millionen Franken über alle Standorte hinweg; im laufenden Jahr sollen die Investitionen auf über 400 Millionen Franken steigen. Hintergrund sind unter anderem mehrere Grossaufträge von Herstellern der stark nachgefragten Medikamenten zur Gewichtsreduktion. Gleichzeitig treibt Bachem den Ausbau neuer Kapazitäten voran: Die erste Bauetappe des Gebäudes K wurde Ende 2025 von der Aufsichtsbehörde Swissmedic inspiziert und freigegeben. Das Unternehmen, das Peptid-basierte Wirkstoffe für Indikationen wie Krebs, Diabetes und Fettleibigkeit liefert und parallel ein Standbein im Bereich Oligonukleotide aufbaut, setzt damit klar auf steigende Nachfrage – auch wenn es bei der kommunikativen Zuspitzung seiner Umsatzziele zurückhaltender geworden ist.
